- Patients
- Clinical Research
- Clinical trials
- ProstACT-Global-002
ProstACT-Global-002
A multinational, multicentre, prospective, randomised, controlled, open label phase 3 study with best standard of care with and without 177Lu-DOTA-rosopatamab for patients with PSMA expressing metastatic castration-resistant prostate cancer progressing despite prior treatment with a novel androgen axis drug
Trial overview
Theranostics
Prostate cancer
III
Number: NCT04876651
GenesisCare Murdoch (Oncology)
Disclaimer:
This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.